Targeting a cancer cell’s “master switch”
May 9, 2016 | City of Hope
According to a new study published in the prestigious scientific journal, Immunity, scientists at City of Hope have unlocked a key component of STAT3 activation, a gene that has long been associated with tumor cell growth and antitumor immune suppression. By exploring how STAT3 is activated in B cells, a major type of immune cell, our researchers have identified a novel target for cancer therapy.
Beating prostate cancer: ‘We’re taking off the brakes’
March 24, 2016 | City of Hope
Researchers at City of Hope believe they are on the verge of significant headway in the treatment of advanced prostate cancer, thanks to new thinking and “staggering” early success.
Antibodies discovery could revolutionize the treatment of cancer
February 2, 2016 | Elise Lamar
Stat, Myc, Myb, Fos, Ras, and Fox: Those bland monosyllables, unfamiliar to most of us, command the respect and fear of oncologists and cancer researchers worldwide. Why? Because they name proteins that drive uncontrollable cell division, metastasis, and/or drug resistance in numerous cancers.
Cancer researcher's work on STAT3 protein gets international recognition
October 4, 2014 | Darrin Joy
Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Hua Yu was recently awarded with the prestigious Humboldt Research Award for her numerous breakthrough discoveries involving STAT3 .
March Grad Student Forum: Jenny Wang
March 21, 2014 | Jenny Wang
Successful breast cancer treatment is often hindered by chemoresistance, metastasis, and tumor recurrence. The existence of a small population of cells, called cancer stem cells, is thought to contribute to these complications.
Scientists uncover important step in tumors' blocking of immune system
March 19, 2014 | Nicole White
Cancers thrive and spread in part because of their ability to create fortresses around themselves that ward off the body’s natural immune defenses, a so-called immunosuppressive microenvironment. A new study sheds light on how a tumor is able to work against the body's immune system, a discovery with the potential to unlock new immunotherapies.
T cell research for prostate cancer gets boost from $1 million gift
February 3, 2014 | Hiu Chung So
Although prostate cancer is often highly treatable, the prognosis for men with metastatic disease remains grim. According to the American Cancer Society, men with distant prostate cancer metastases have a five-year survival rate of 28 percent, and almost 30,000 men die from the disease each year in the United States.